Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1

NCT06718244 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL: single dose of Inaticabtagene autoleucel

Sponsor

Ruijin Hospital